High dose rate192Ir versus high dose rate60Co brachytherapy: an overview of systematic reviews of clinical responses of gynecological cancers from 1984 to 2020

Efficacy of high-dose-rate brachytherapy with different radiation source activities among cervical cancer patients and risk factors for long-term outcomes: A 6-year retrospective study

PURPOSE

This study aimed to assess the impact of dose rates due to natural decay of Iridium-192 sources and the risk factors of clinical outcomes for cervical cancer patients treated with high-dose-rate (HDR) brachytherapy.

METHODS AND MATERIALS

Four ninety-four patients were divided into relatively-high-radioactive (rHR), relatively-medium-radioactive (rMR), and relatively-low-radioactive (rLR) groups for retrospective treatment response comparison. The short-term outcomes were evaluated using the 1-month /3-month follow-up results based on RECIST 1.1. Local recurrence-free survival (LRFS) and metastatic recurrence-free survival (MRFS) were selected as long-term outcomes. A class of transformation models with adaptive lasso was applied to assess the risk factors of long-term outcomes.

RESULTS

No significant difference was identified in short- or long-term outcomes of different radioactive groups. Subgroup analyses demonstrated similar findings. In multivariate factor analysis, advanced stage was significantly associated with higher risk of local recurrence and metastatic recurrence (HR = 1.66, 95%confidence interval [CI] = 1.14-2.43, p = 0.008; HR = 1.57, 95%CI = 1.23-2.00, p < 0.001). Significant associations were observed between local recurrence and pathology, and between metastatic recurrence and pre-treatment serum indices, respectively (HR = 8.62, 95%CI = 2.28-32.60, p = 0.002; HR = 1.98, 95%CI=1.20-2.26, p = 0.008).

CONCLUSIONS

Overall, there was no significant difference in long- or short-term efficacy of the HDR brachytherapy among the groups with different levels of activity of radiation sources. Stage, pathology, and pretreatment serum indices were crucial factors that affected the long-term outcomes.

Radiobiological and dosimetric comparison of 60Co versus 192Ir high-dose-rate intracavitary-interstitial brachytherapy for cervical cancer

BACKGROUND

High-dose-rate (HDR) intracavitary-interstitial brachytherapy (IC-ISBT) is an effective treatment for bulky, middle, and advanced cervical cancer. In this study, we compared the differences between 60Co and 192Ir HDR IC-ISBT plans in terms of radiobiological and dosimetric parameters, providing a reference for clinical workers in brachytherapy.

METHODS

A total of 30 patients with cervical cancer receiving HDR IC-ISBT were included in this study, and IC-ISBT plans for each individual were designed with both 60Co and 192Ir at a prescribed dose of CTV D90 = 6 Gy while keeping the dose to OARs as low as possible. Physical dose and dose-volume parameters of CTV and OARs were extracted from TPS. The EQD2, EUBED, EUD, TCP, and NTCP were calculated using corresponding formulas. The differences between the 60Co and 192Ir IC-ISBT plans were compared using the paired t-test.

RESULTS

In each patient's 60Co and 192Ir IC-ISBT plan, the average physical dose and EQD2 of 60Co were lower than those of 192Ir, and there were statistically significant differences in D2cc and D1cc for the OARs (p < 0.05); there were statistically significant differences in D0.1 cc for the bladder (p < 0.05) and no significant differences in D0.1 cc for the rectum or intestines (p > 0.05). The EUBED ratio (60Co/192Ir) at the CTV was mostly close to 1 when neither 60Co or 192Ir passed their half-lives or when both passed two half-lives, and the difference between them was not significant; at the OARs, the mean value of 60Co was lower than that of 192Ir. There was no statistical difference between 60Co and 192Ir in the EUD (93.93 versus 93.92 Gy, p > 0.05) and TCP (97.07% versus 97.08%, p > 0.05) of the tumors. The mean NTCP value of 60Co was lower than that of 192Ir.

CONCLUSIONS

Considering the CTV and OARs, the dosimetric parameters of 60Co and 192Ir are comparable. Compared with 192Ir, the use of 60Co for HDR IC-ISBT can ensure a similar tumor control probability while providing better protection to the OARs. In addition, 60Co has obvious economic advantages and can be promoted as a good alternative to 192Ir.

A Dosimetric evaluation of a high dose rate cobalt-60 brachytherapy source using shielded, single and multi-channel cylinder applicators for gynecological cancers

Vaginal brachytherapy is a standard method for preventing the recurrences of malignancies in the treatment of gynecological cancers. Cylindrical applicators are usually employed in high dose rate cobalt-60 source brachytherapy after abdominal hysterectomy or bilateral salpingo-oophorectomy treatment. The aim of this study is to conduct an assessment of dosimetric properties of single channel, multichannel, and shielded cylinder applicators. This study utilizes a pelvis phantom with three different volumes of bladder and rectum to perform dose measurement around the cylindrical applicators. GAFCHROMIC EBT3 model film was used to measure dose distributions in water phantom around the bladder, rectum, applicator, and CTV. In order to properly compare the performance of the shielded applicator with multichannel and single channel applicators, we consider the both cases of a one-sided CTV and two CTVs placed on both sides of the vagina. Dose-volume histograms analysis shows no statistically significant difference in tumoral region for the two types of CTV between cylindrical applicators. The V_120%, V_100% and D_95% values of target volume were 47.36%. 91.46%, and 3.99Gy for multi-channel cylinder applicator, 60.2%, 95.02%, and 3.99Gy for single channel cylinder applicator, respectively. Statistical analysis reports D_0.1cc, D_1cc, and D_2cc for the multichannel applicator demonstrates a significant dose reduction in bladder compared with single channel. The V_120%, V_100%, and D_95% values of target volume were 55.50%. 97.90%, and 3.91Gy for multi-channel cylinder applicator with four active channels (MCC-4), 41.56%, 92.10%. and 4.13Gy for shielded cylinder applicator, respectively. Statistical analysis reports D_0.1cc, D_1cc and D_2cc for the MCC-4 demonstrates a noticeable dose reduction in bladder and rectum compared with Shielded channel. The results indicate that employing multichannel applicator in vaginal high dose rate cobalt-60 source brachytherapy can reduce the received dose to organs at risk without any significant loss of received dose in CTV, which is contributed to its asymmetric or symmetric dose distribution that depend on which channels are activated.